. 2019 Aug 4;5(3):e12233. doi: 10.2196/12233
©Katherine Keenan, Katharine Footman, Munnaf Sadekin, Kate Reiss, Reena Yasmin, Hannah Franklin, Kathryn Church. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 04.08.2019.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on http://publichealth.jmir.org, as well as this copyright and license information must be included.
Figure 3.
Number of calls by month according to brand of menstrual regulation drug purchased (September 2013-August 2016).